When combined with p16 and Ki-67 immunohistochemistry, this approach allows better discrimination of transforming CIN lesions, prediction of regression or progression, and guidance for individualized management (10).In the present case, however, such molecular tests, including promoter DNA methylation analysis and p16/Ki-67 dual staining, were not performed due to diagnostic limitations at that time. This evidence concerns the gene MKI67 and cervical squamous intraepithelial neoplasia.